Evaxion files amendment to registration statement related to 2025 EIB debt settlement agreement
The settlement's effective conversion price represented an 89% premium to the share price at market close on July 10, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Evaxion (NASDAQ: EVAX) filed an amendment to its registration statement covering possible EIB share resales tied to its 2025 debt settlement. The filing concerns shares issuable upon exercise of warrants held by the European Investment Bank, not a new capital raise.
Under the agreement finalized in July 2025, EIB converted €3.5 million of its €7 million loan into warrants to subscribe for 38,450,000 ordinary shares at an effective conversion price of $4.87 per ADS. Evaxion receives no proceeds from EIB's share resales but may receive up to DKK 9,612,500 (approximately $1.5 million) in aggregate gross proceeds from warrant exercises. The registration statement is not yet effective.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointThe July 2025 settlement canceled €3.5 million of Evaxion's €7 million EIB loan.
- Minor point. Forward-looking: it has not happened yet and may not happen.Warrant exercises may provide up to DKK 9,612,500 (approximately $1.5 million) in aggregate gross proceeds.
- Minor pointThe $4.87 per ADS effective conversion price represented an 89% premium to the July 10, 2025 closing share price.
Negative
- Moderate point. Forward-looking: it has not happened yet and may not happen.Warrants issued in the settlement permit subscription for 38,450,000 ordinary shares, creating potential dilution.
- Minor pointEIB's share resales provide no proceeds to Evaxion.
Details
Market Reaction – EVAX
On Nov 9, the day this news came out, the latest delayed price for EVAX is 8.00% below the previous close. Our momentum scanner has recorded 7 alerts for this stock so far that day. The latest delayed price is $2.76. Relative volume is elevated at 2.7x what this stock usually trades by this time of day.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Debt converted
- €3.5 million of a €7 million loan
- 2025 EIB debt settlement agreement
- Shares underlying warrants
- 38,450,000 ordinary shares
- Warrants issued under the 2025 settlement
- Effective conversion price
- $4.87 per ADS
- 2025 EIB debt settlement agreement
- Premium to share price
- 89%
- Premium to the July 10, 2025 market-close share price
- Potential additional gross proceeds
- Up to DKK 9,612,500 (approximately $1.5 million)
- May be received if EIB exercises the warrants
Key Terms
form f-1 regulatory
warrants financial
ads financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
COPENHAGEN, Denmark, November 9, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, has filed an amendment to its registration statement on Form F-1 related to the 2025 debt settlement agreement with The European Investment Bank (EIB) with the US Securities and Exchange Commission.
The registration statement was originally filed in November 2025, as required under the agreement under which EIB converted debt to warrants, and relates solely to the possible resale by EIB of shares issuable upon exercise of those warrants. Evaxion is not conducting a capital raise.
Evaxion and EIB finalized the agreement in July 2025 under which EIB converted
Evaxion is not selling any securities under the registration statement and will not receive any of the proceeds from the sale of the ordinary shares represented by ADSs by the selling shareholder (EIB). However, we have received a partial debt cancellation of
When finalized in July 2025, the agreement immediately increased Evaxion’s equity by
The registration statement has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Contact information
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai
About Evaxion
Evaxion is a pioneering clinical-stage TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer as well as infectious and autoimmune diseases.
With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development.
We have developed a pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.
For more information about Evaxion, AI-Immunology™ and our pipeline, please visit our website.
Forward-looking statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Is Evaxion's amended EIB registration statement a new capital raise?
No. The registration statement relates solely to possible EIB resales of shares issuable upon warrant exercise under the 2025 debt settlement. Evaxion will receive no proceeds from those resales, although warrant exercises may provide up to DKK 9,612,500, or approximately $1.5 million, in aggregate gross proceeds.